Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857590 | 1.00 | GAA (0.42) | GAANPY5ROPRM1OPRD1OPRK1 | |
| SCHEMBL1857588 | 1.00 | GAA (0.42) | GAANPY5ROPRM1OPRD1OPRK1 | |
| SCHEMBL1107460 | 0.91 | GAA (0.40) | GAANPY5ROPRM1OPRD1OPRK1 | |
| SCHEMBL2643987 | 0.90 | GAA (0.44) | GAANPY5ROPRM1OPRD1OPRK1 | |
| SCHEMBL1107378 | 0.90 | GAA (0.44) | GAANPY5ROPRM1OPRD1OPRK1 | |
| SCHEMBL8152205 | 0.89 | GAA (0.51) | GAANPY5ROPRM1OPRD1OPRK1 | |
| SCHEMBL1860369 | 0.89 | GAA (0.43) | GAANPY5ROPRM1OPRD1OPRK1 | |
| SCHEMBL1860368 | 0.89 | GAA (0.43) | GAANPY5ROPRM1OPRD1OPRK1 | |
| SCHEMBL1860370 | 0.89 | GAA (0.43) | GAANPY5ROPRM1OPRD1OPRK1 | |
| SCHEMBL2652714 | 0.83 | GAA (0.35) | GAANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| EP-2046755-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012227-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | GAA 150/4885NPY5R 2934/4885OPRM1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.